FDA Levaquin Warning: Serious Side Effects Could Become Permanent

By | Levaquin, Uncategorized

In mid-May 2016, the US Food and Drug Administration (FDA) issued a new safety warning about Levaquin (fluoroquinolone). The regulatory agency warned of serious side effects that could become permanent.

Levaquin side effects mentioned in the warning include:

  • Tendon, joint, and muscle pain
  • “Pins and needles” prickling sensation
  • Confusion
  • Hallucinations

According to the FDA, these side effects can occur simultaneously, and can become permanent.

With this new information, the FDA ordered that drug labels for Levaquin and other fluoroquinolone drugs be updated.

We are here to help you.

Do you have a Levaquin case? We can help you determine if filing a Levaquin lawsuit is the right decision. Our law firm offers free, no obligation case evaluations.

Contact Carey Danis & Lowe today. Call 800.721.2519, or complete our confidential online form.

Levaquin Lawsuit Update: Neurological Side Effects

By | Levaquin, Pharmaceutical litigation, Uncategorized

Levaquin MDL Settlement Update: Phase 1 Plaintiffs Have Signed a Settlement AgreementA doctor at the University of South Carolina submitted a petition to the U.S. Food and Drug Administration (FDA) seeking that the Black Box warning for the antibiotic drug Levaquin be updated to reflect the risk for a neurological disorder called Mitochondrial Toxicity. The Black Box warning already includes information on tendon rupture.

Dr. Charles Bennett submitted the petition after reading a report written by the FDA in 2013 about Mitochondrial Toxicity. This report has not been released, and was acquired through use of the Freedom of Information Act, according to a press release from the Quinolone Vigilance Foundation.

The FDA report draws a link between drugs containing fluoroquinolone, such as Levaquin, and incidences of Mitochondrial Toxicity that lead to Parkinson’s, Alzheimer’s, and ALS.

As the many sufferers of Levaquin injuries understand, this antibiotic poses serious health risks to its consumers. Therefore, if Levaquin is the cause of Mitochondrial Toxicity, it is of the utmost importance to educate patients and health care providers about this serious drug side effect through updating the Levaquin Black Box warning.

Carey Danis & Lowe represents victims in Levaquin lawsuits, and through hearing the devastating stories of our clients, we have a deep understanding of the importance of drug warnings.

Carey Danis & Lowe, Advocates of Levaquin Victims

A St. Louis law firm that practices defective drug litigation, Carey Danis & Lowe represents individuals who have been injured by Levaquin. Our attorneys are currently investigating Levaquin cases, and are available to discuss legal options and compensation eligibility with those who believe that they have been injured after using Levaquin.

Carey Danis & Lowe offers free initial case evaluations.

If you have been harmed by Levaquin, we encourage you to share your Levaquin story with one of our defective drug lawyers today. You can reach our law firm by phone at 800.721.2519, or by completing our confidential personal injury claim form.


We look forward to assisting you in any way that we can.

FDA Releases Safety Communication about Levaquin & Peripheral Neuropathy

By | Levaquin, Pharmaceutical litigation, Uncategorized

Antibiotic Levaquin Tendon Rupture Tendinitis LawsuitThe U.S. Food and Drug Administration (FDA) recently ordered that an update be made to the drug labels for fluoroquinolone medications, which includes the antibiotic drug Levaquin. Released on August 15, 2013, the FDA’s safety communication calls for improved information on a fluoroquinolone side effect, peripheral neuropathy.

The FDA states that peripheral neuropathy is a severe form of nerve damage that has the potential to permanently injure patients. If patients taking a fluoroquinolone drug, such as Levaquin, begin to notice peripheral neuropathy symptoms, the FDA recommends stopping use of the medication and seeking assistance from a health care provider. Peripheral neuropathy symptoms include pain, numbness, and tingling in the arms, hands, legs, and feet.

Updating the medication guide for fluoroquinolone drugs to include not only information about peripheral neuropathy will provide patients with important safety information that has the potential to prevent future injuries.

Levaquin is primarily known for causing tendon damage. Carey Danis & Lowe Levaquin lawsuit attorneys provide legal counsel to individuals who claim to have experienced either tendon tears or tendon ruptures associated with Levaquin use. Other tendon complications linked to Levaquin use include tendonitis, tendon inflammation, and joint immobility.

Carey Danis & Lowe is currently accepting Levaquin lawsuits. For a free legal evaluation of your Levaquin case and for advice from a nurse, contact Carey Danis & Lowe by calling 800.721.2519 or by submitting a personal injury claim form.

Levaquin Lawsuit News: Antibiotic Drug Levaquin Linked to Tendon Damage and Many Other Serious Side Effects

By | Levaquin, Pharmaceutical litigation, Uncategorized

Levaquin MDL Settlement Update: Phase 1 Plaintiffs Have Signed a Settlement AgreementIn current Levaquin lawsuit news, it has become apparent that fluoroquinolones, like Levaquin (levofloxacin), is the cause of more than just tendon damage, as previously understood. In a recent New York Times article,  fluoroquinolone antibiotics have recently been linked to other serious problems affecting ocular and renal health.

The article goes on to cite the fact that this class of antibiotics has been over-prescribed by doctors. According to one pharmacological epidemiologist, prescribing a drug like Levaquin to treat certain infections is sometimes overkill. It appears that the harm caused by Levaquin and other fluoroquinolone antibiotics could be lessened by exploring other treatment options.

Individuals who have taken Levaquin, and have experienced health complications following use, have most often reported incidences of tendon damage, tendon rupture, and tendonitis. Though, in addition to tendon problems, recent research published in The Journal of the American Medical Association reveals that the use of fluoroquinolones like Levaquin has also played a key role in increasing the risk of retinal detachment and kidney failure.

In 2008, the U.S. Food and Drug Administration ordered manufacturers of fluoroquinolones to include a boxed warning about the risk of developing tendonitis and tendon damage while using these kinds of antibiotics. Following the studies showing a connection between Levaquin and damage to retinal and renal health, the FDA recently updated this order to cover information about the link between fluoroquinolone use and neuromuscular problems.

The manufacturer of Levaquin, Janssen Pharms, faces over 2,000 Levaquin lawsuits.

Carey Danis & Lowe Levaquin lawyers are currently investigating Levaquin cases. If you or someone you love has been injured through the use of Levaquin, contact Carey Danis & Lowe today for a free legal evaluation and for assistance in filing a Levaquin lawsuit.

Contact Carey Danis & Lowe by calling 800.721.2519 or by submitting a personal injury claim form.

Levaquin MDL Settlement Update: Phase 1 Plaintiffs Have Signed a Settlement Agreement

By | Levaquin, Pharmaceutical litigation, Uncategorized

Levaquin MDL Settlement Update: Phase 1 Plaintiffs Have Signed a Settlement AgreementCourt convened on January 8, 2013 for a Status Conference for Levaquin lawsuits that have been consolidated into In Re: Levaquin Products Liability Litigation, the Multi-District Litigation (MDL) that is being heard by U.S. District Judge John R. Tunheim in the U.S. District Court for the District of Minnesota. Though the plaintiffs’ committee and the defendant’s representation only met for a half hour, they brought forth important updates in the Levaquin MDL.

According to information provided by the Defendants, there are currently 1000 cases pending in the Levaquin MDL “that are in the process of settling, and will soon be dismissed.” Once the settlement of these 1000 cases is complete, the Levaquin MDL will consist of 900 cases.

In state Levaquin lawsuits, there is a mass tort litigation that has been established in a New Jersey state court with 1400 cases that remain open. Further updates about the New Jersey mass tort Levaquin litigation will be available after the next Status Conference, which is scheduled for January 25. To date, the New Jersey mass tort Levaquin litigation represents the most Levaquin lawsuits being heard by a state court.

As the Levaquin MDL Status Conference minutes detail, there are “three cases pending in Illinois…one case in Pennsylvania and one in Mississippi.”

As to the status of settlement negotiations in the Levaquin MDL, both parties have come to a settlement agreement in Phase 1 cases. The plaintiffs with cases consolidated into the Phase 1 pool have signed the settlement agreement.

The plaintiffs’ committee has since begun work on plans to allocate the settlement funds. For cases consolidated into Phase 2 and Phase 3 pools, both parties are still working on negotiating a settlement agreement.

Levaquin is a drug manufactured by OrthoMcNeil Pharmaceutical, Inc., a Johnson & Johnson subsidiary, that is prescribed to patients suffering from a bacterial infection of the lungs, skin, and urinary tract. Some patients who were prescribed Levaquin, and subsequently ingested the drug to treat their bacterial infection, experienced serious side effects.

The drug Levaquin has been known to inflict severe tendon damage, including tendon inflammation, tendonitis, joint immobility, and tendon rupture.

Minnesota Levaquin MDL and New Jersey Levaquin Mass Tort Plaintiffs Claim Serious Tendon Damage

By | Levaquin, Pharmaceutical litigation, Uncategorized

Minnesota Levaquin MDL and New Jersey Levaquin Mass Tort Plaintiffs Claim Serious Tendon DamageLevaquin, a drug manufactured by a Johnson & Johnson subsidiary – OrthoMcNeil Pharmaceutical, Inc. – is the topic of several lawsuits around the country that have since been consolidated into a Multi-District Litigation based in Minnesota. A mass tort litigation has been arranged in a New Jersey court.

Levaquin is a drug used to treat bacterial infections occurring in the lungs, urinary tract, skin, and other areas of the body. It soon became apparent that Levaquin was the cause of serious and painful side effects, primarily targeting patients’ tendons. Plaintiffs in the Minnesota MDL and the New Jersey mass tort litigation claim that Levaquin caused tendonitis, tendon rupture, joint immobility, and other joint complications.

As a result of increasing adverse event reports filed with the U.S. Food and Drug Administration (FDA), OrthoMcNeil was ordered to update Levaquin’s label with information regarding Levaquin tendon damage.

According to court minutes from a Status Conference held in the U.S. District Court for the District of Minnesota on December 4, 2012, the parties involved in the MDL are currently in negotiations relating to a three phase settlement. The goal of the settlement negotiations is to have the terms of the settlement defined early this year.

One case in the Minnesota Levaquin MDL is set to go to trial on March 5, 2013. Prior to that date, as outlined in the Status Conference court minutes, the Defense intends to put a number of motions in limine, and in particular the Defense is aiming to exclude expert testimony provided by a doctor. A ruling has not yet been made about the Defense’s request to put motions in limine.

The next Status Conference for the Minnesota Levaquin MDL is scheduled for January 8, 2013.

As detailed in an updated case document released in mid-December 2012, there are currently 1,835 cases pending in the New Jersey Levaquin mass tort litigation. The most recent case filed with the New Jersey court was done so on December 10, 2012. Bellwether trials in the New Jersey court have been scheduled for June of this year.

If you or a loved one has experienced one or more of the serious side effects linked to the use of Levaquin, such as tendonitis, tendon rupture, or other tendon damage, lawyers at Carey Danis & Lowe can help you and your loved one win the compensation for such an undeserved amount of suffering, pain, and losses.

Our experienced pharmaceutical product liability trial lawyers understand the importance of holding pharmaceutical giants like Johnson & Johnson and OrthoMcNeil Pharmaceutical, Inc. responsible for putting defective drugs onto the market. We work closely with our clients in Levaquin lawsuits to win them the justice they so rightfully deserve.

To file a Levaquin lawsuit, contact a lawyer at Carey Danis & Lowe today by calling 800.721.2519.

Levaquin Lawsuit Recently Filed in Minnesota

By | Levaquin, Pharmaceutical litigation, Uncategorized

Published August 30, 2012 on

In early August, a Minnesota man filed a lawsuit against the manufacturer of Levaquin, Ortho McNeil Janssen Pharmaceuticals, a manufacturing unit of Johnson & Johnson. The man, Richard Johnson, stated in his pharmaceutical liability claim that the drug’s manufacturer neglected to supply adequate health warnings about the use of Levaquin and its link to tendon rupture.

Johnson suffered a rotator cuff tear, and has linked his use of Levaquin, an antibiotic prescribed to treat urinary tract infections, pneumonia, meningitis, cellulitis, and respiratory tract infections, to the damage inflicted on his rotator cuff tendons. Johnson’s case now becomes an addition to the products liability litigation regarding Levaquin in the District Court, District of Minnesota in Minneapolis. Levaquin lawsuits have been combined into multidistrict litigation (MDL) in Minnesota.

In 2008, in response to reports of severe tendon damage and tendonitis, the U.S. Food and Drug Administration (FDA) required manufacturers of fluoroquinolones, a category of antibiotic which includes Levaquin, update the black box label on their drugs to include a detailed and complete warning about the risk of life-altering tendon deterioration and rupture. It has been reported that the manufacturer of Levaquin made a paltry effort at such drug transparency in an attempt to increase drug distribution and profits.